In chronic myeloid leukemia (CML) the classical 9;22 translocation results in a BCR-ABL fusion gene, which encodes chimeric BCR-ABL fusion 210 kD oncoproteins (p210BCR-AeL). The two main ~2 1 0 "~~~ fusion variants in CML, M a 2 and b3a2 are examples of well characterized antigens expressed by malignant cells. The possibility of an immunotherapeutic approach involving the fusion part of p210BCR-A6L in CML has previously been illustrated by observed peptide binding t o major histocompatibility complex (MHC) class I alleles and by demonstrating the immunogenicity of p210BCR-ABL breakpoint peptides. In this report we show that in vitro immunization of human T cells with a 17 amino acid (aa) peptide representing the p210BCR-A6L fusion region resulted in peptide specific CD4' T-cell lines designated P4, P6, and HE t(9; 22)(q34;qll) translocation in leukemic cells T from chronic myeloid leukemia (CML) patients results in a fusion gene known as BCR-ABL. The breakpoint on chromosome 9 is nearly always located upstream of ab1 exon a2,' whereas the breakpoint on chromosome 22 is located either between bcr exons b2 and b3 or between exons b3 and b4.2.3 These differently fused genes encode in principle two variant 210 kD proteins4: p21ObZa2 or ~210~'"'. In approximately 40% of CML patients, the b3u2 fusion oncoprotein is detected, in another 40% the b2a2 protein, whereas in about 20%, due to alternative splicing,5 both b3a2 and b2a2 mRNA are present.6-" Presumably, also by virtue of alternative splicing, relatively low amounts of a third BCR-ABL protein of 190 kD molecular weight p190""', primarily associated with acute lymphoblastic leukemia, are detectable in cells from CML patients."." P210BCR-ABL and p 1 90BCR-ABL, known for enhanced tyrosine-kinase activity compared with the activity of the physiological product of c-abl,I4 are involved in the process of Junction region amino acid (aa) sequences in p210BCR-ABL are examples of well-characterized antigens expressed by leukemic cells. In a murine model a p2 10h3"' breakpoint representing peptide was able to induce peptide specific major histocompatibility complex (MHC) class I1 restricted T cells in vivo." We have recently shown that immunization of human T cells in vitro P7. HLA DR4 (DRB1*0401) restricted T-cell line P4 and several subsequently derived clones recognized HLA-DRB?*OMl and p210b3"*-mRNA expressing blasts from an allogeneic patient with CML in blast crisis. Recognition appeared DR expression-dependent. No responses were observed with DR4 positive p210BCR"BL negative cells or with ~2 1 0~' leukemic cells with absent or insufficient expression of DR4. These observations indicate that oncoprotein p2IObSe can be degraded and processed for presentation by MHC class ll molecules at the surface of leukemic cells. The BCR-ABL fusion region is in all likelihood presented as peptides by HLA DR and thus capable t o act as a distinctive tumor antigen t o peptide specific CD4' T cells.
P7. HLA DR4 (DRB1*0401) restricted T-cell line P4 and several subsequently derived clones recognized HLA-DRB?*OMl and p210b3"*-mRNA expressing blasts from an allogeneic patient with CML in blast crisis. Recognition appeared DR expression-dependent. No responses were observed with DR4 positive p210BCR"BL negative cells or with ~2 1 0~' leukemic cells with absent or insufficient expression of DR4. These observations indicate that oncoprotein p2IObSe can be degraded and processed for presentation by MHC class ll molecules at the surface of leukemic cells. The BCR-ABL fusion region is in all likelihood presented as peptides by HLA DR and thus capable t o act as a distinctive tumor antigen t o peptide specific CD4' T cells. 0 1996 by The American Society of Hematology.
with a similar peptide resulted in a b3a2 peptide-specific HLA DRB 1 *1501 restricted CD4' T-cell line. '" In this report we show that a 17-aa peptide representing the p210""' breakpoint region can also be presented by DRB1*0401 molecules. In vitro immunization of T cells from a healthy donor with this b3a2 peptide resulted in DR2(DRB1*1501/DRB5*0101) and DR4(DRB1*0401/ DRB4*0101) restricted peptide-specific proliferative CD4' T-cell lines and clones. The DRB1*0401 restricted T-cell line P4 and several P4-derived clones recognized DRB1*0401 and p210h-'"' mRNA expressing blasts from a CML patient in blast crisis.
MATERIALS AND METHODS
This study was approved by a local ethical committee. Blood samples were collected from patients and healthy donors after informed consent only.
Preparation of BCR-ABLh-'"' Specific T Cells and Clones
Blood was obtained at regular intervals from a healthy male blood group A Rh-D negative donor P with the following HLA type: A2; B7, B44; Cw5. Cw7; DR4(DRB1*0401), DR53(DRB4*0101); DR2(DRBl*1501), DR51(DRB5*0101); DQ6, DQS; DPB*0201, DPB*0401. Peripheral blood mononuclear cells (PBMC), 20 to 30 x IO' , were isolated from whole blood using Ficoll-amidotrizoate centrifugation and cultured at 37°C in 5% COz. Tissue culture medium (Iscove's Modified DMEM, Gibco-Life Technologies, Paisley, Scotland) was supplemented with antibiotics (100 IU/mL penicillin) and 10% to 15% autologous heat inactivated serum. Final 17mer b3a2 or b2a2 peptide concentration was 10 pg/mL (approximately 6 nmol/mL). Responding cells were restimulated with IO' irradiated autologous PBMC and peptide every 10 days. From day 40 an additional 2 X lo7 allogeneic pooled irradiated PBMC from six random healthy donors and lo7 autologous irradiated PBMC were used as antigen presenting cells (APC) for restimulation. From this moment on, 10% T-cell growth factor (TCGF, Lymphocult, Biotest) was added to the tissue culture medium, after which T-cell cloning was performed by limiting dilution.
Peptides
Amino acid sequences of the ~210'~"' and ~2 1 0 6~"~ fusion region and of its physiological counterparts 1A-a2 and b3b4 were used to design the breakpoint representing 17 aa length peptides (b2a2: Lysine (K) is the b3a2 joining amino acid as is glutamine(E) in the b2a2 protein.
The peptides were synthesized using solid-phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422, Langenfeld, Germany) with the Fmoc procedure," purified by C18 reversed phase high performance liquid chromatography (HPLC), and characterized by amino acid sequence analysis and mass spectrometry. Peptides were stored at -70°C in aliquots of 1 mL in a concentration of 10 mglmL in phosphate-buffered saline (154 mmolL NaCI, 1.4 mmol/L Na,HPO,, pH 7.5).
Patient Material
Cells designated HB were from a male, 44 years old, blood group A Rh-D positive patient with CML in myeloid blast crisis. HLA type: AI, A2; B37, B40; Cw3, Cw6; DR1(DRB1*0101); DR4(DRB 1 *0401), DR53(DRB4*0101); DQ8. A stable high leukocyte count (20 to 35 X lo9& >90% blast cells) was observed under maintenance chemotherapy (6-mercaptopurine, hydroxyurea) and prednisone. Cytogenetics showed the 9; 22 translocation, as well as translocation (12; 14 Blasts from CML patient FM (male, 44 years), with an accelerated phase of the disease, were b2a2 positivelb3a2 negative. HLA type: A2, A3; B12, B44, B47; Cw5, Cw6; DR7, DRII, DR52, DR53; DQ2, DQ7.
Leukemic cells from b2a2 positivelb3a2 positive CML patient IL (female, 43 years) were collected during blast crisis and kindly provided by Dr H.J. Kolb, Munich, Germany, HLA type: A2; B7; DR15, DR51; DQ6, DQ1.
Cells ES were obtained from a 34-year-old man with CML in chronic phase, HLA type: AI, A2; B8, B12; Cw5, Cw7; DR4(DRB1*0404), DR17, DR52, DR53; DQ2, DQS. Blasts showed the 9; 22 translocation and were b2a2 negativelb3a2 positive by RT- 
MHC Blocking
HLA-DR blocking experiments were performed as described"' using murine MoAb B8.1 l.2.2J The DQ restricted anti-Mycobacterium leprae CD4' clone R3F10" was used to exclude aspecific blocking by anti-DR.
RESULTS

BCR-ABL Breakpoint Peptide-Specific T-cell Lines
Primary in vitro immunization of peripheral blood lymphocytes (PBL) from a healthy donor with 17mer h3a2 peptide resulted in three CD4' b3a2 peptide-specific T-cell lines(P4, P6, and P7). There was no reactivity of any of these cell lines to the physiological 17mer counterparts b3b4 and IA-a2 or to h2a2 (Fig 1) . Presentation by APC was essential because no proliferation to peptide was seen in the absence of APC. Minimal peptide concentration required for inducing a response was approximately 50 ng/mL (30 nmoV L) for all T-cell lines.
MHC Restriction of BCR-ABL b3a2 Peptide-Specijc TCell Lines
MHC blocking experiments indicated that the respowes of P4, P6, and P7 to the b3n2 peptide were HLA-DR re- stricted. Anti-DR MoAb B8.11.2 inhibited the proliferation of P4, P6, and P7 induced by b3a2 peptide loaded APC, but had no effect on the response of HLA-DQ restricted Tcell clone R3F10 to Mycobacterium leprae peptide (data not shown). A panel of HLA typed PBMC and B-LCL was used to identify the restriction elements for these three T-cell lines (Table 1) . DR4(DRB1*0401) positive APC were required to present the 17 aa peptide to the responding T-cell line P4. T-cell lines P6 and P7 appeared DR2 restricted.
Proliferative Response of P4 to CML Blasts
BCR-ABL peptide-specific T-cell lines (P4, P6, and W )
and subsequently derived clones were tested with HLA-DR4 BCR-ABLb3"2 mRNA positive cells from patient HB. As shown in Fig 2, T-cell line P4 and six of its clones were stimulated by blasts HB to proliferate. No proliferative responses of the other T-cell lines were observed.
Recognition of CML Blasts by T Cells P4 is Specific and DR Restricted
Responses of T-cell line P4 to leukemic control cells without expression of DR4(DRB 1*0401) andor BCR-ABLh3"' mRNA and to BCR-ABL mRNA negative EBV-LCL derived from patient HB are depicted in Table 2 . Preincubation of CML blasts from patient HB with IgG anti-DR MoAb B8.11.2 completely inhibited the proliferative response of P4 T cells (Fig 3) . In keeping with a DR expression-dependent response of P4 cells to CML blasts HB, enrichment for DR positive tumor cells by FACsorting resulted in an enhanced T-cell response (Table 3) . Reduced DR (and perhaps also ~2 1 0 '~) expression as a consequence of in vitro blast cell differentiation, as evidenced by increased CD15 and to a lesser extent CD33 and CDw65 expression, was associated with a diminished T-cell response (Table 4) .
DISCUSSION
The fusion regions in BCR-ABL oncoproteins have been acknowledged as potential tumor-specific targets for an immunotherapeutic approach of associated malignancies."
HLA class I and class I1 molecules capable of presenting BCR-ABL breakpoint peptides have recently been identified.20.z8 Intermediate to high-affinity MHC binding of BCR-ABL peptides has been observed.28 However, evidence for intracellular processing of endogenous BCR-ABL proteins leading to the presentation of MHC-bound native BCR-ABL peptides at the cell surface is lacking thus far. The present study suggests that such processing of p2 10BCR-ABL proteins may, in fact, occur by showing recognition of BCR-ABLb3a2 expressing CML blasts by a BCR-ABLb3"2 breakpoint representing peptide-specific CD4' T-cell line and several of its clones in an HLA DR4-restricted fashion. This phenomenon cannot be explained as recognition of exogenous blast cellderived BCR-ABL peptide presented by APC (from patient or T-cell donor origin). FACS sorted CML blasts from patient HB, 96% double positive for DR and progenitor marker CD34, were effective in stimulating P4 cells to proliferate making a role of patient-derived residual CD34 negative professional APCZ9 unlikely. Furthermore, incubation of the T-cell line P4 with BCR-ABL peptide in the absence of any added APC did not result in proliferative activity above the background level (data not shown).
Although we cannot fully exclude the possibility that this apparent specific T-cell response is based on cross reactivity with a DR bound peptide3' unrelated to p210BCR-ABL presented by these particular allogeneic CML blasts, several indications argue against such an alternative explanation. First, p210BCR-ABL negative B-LCL from the same patient were not recognized, making cross reactivity with, for instance, an HLA-derived peptide3' unlikely. Second, several other allogeneic CML cells without expression of either the appropriate HLA molecules andor BCR-ABLh3"' mRNA were unable to stimulate T cells to proliferate. Nonspecific, eg, leukemic blast-derived, cytokine-mediated T-cell proliferation is virtually excluded by the fact that two other BCR- Four fresh HB blast samples obtained at different occasions were cultured, tested, and phenotyped for myeloid and progenitor cell markers.
The response of P4 is given as the percentage of the maximal response to autologous APC with 10 pg/mL (6 nmol/mL) 17mer b3a2 peptide.
ABL peptide-specific non-DR4 restricted CD4' T-cell lines did not respond to the same CML blasts. Such a nonspecific stimulatory effect is also difficult to reconcile with the HLA-DR dependency of the T-cell responses. One would have to assume a unique sensitivity of these DR-restricted and peptide-specific T cells P4 for an immature myeloid differentiation stage-specific cytokine produced by certain CML blasts only. The production of which is furthermore inhibited by anti HLA-DR antibodies. Experiments are underway in our laboratory to solve this issue by searching for the BCRABLb"' junction region aa sequence among the many different peptides eluted from immunopurified HLA-DR molecules of CML blasts of patient HB. Intriguing recent findings of very low numbers of BCR-ABL transcripts in some healthy individuals3* are compatible with BCR-ABL peptide-specific immune surveillance. Studies are in order to establish if the presence or absence of BCR-ABL mRNA in healthy individuals is correlated with their ability to mount T-cell responses to BCR-ABL peptides. The present observations, albeit confined to a single donor-patient combination, provide a first argument for the feasibility of peptide-specific adoptive immunotherapy or possibly BCR-ABL peptide vaccination in CML.
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NOTE ADDED IN PROOF
During the review process of this manuscript Bocchia et a133 reported in this journal that cytolytic HLA class I-restricted human T cells directed against BCR-ABL fusion sequence encoded synthetic peptides could be established. However, recognition of native BCR-ABL peptides was not yet demonstrated.
